Caspofungin for the Treatment of Immunocompromised and Severely III Children and Neonates with Invasive Fungal Infections
Caspofungin is the first member of the echinocandin class of antifungals to receive an indication for the use in infants, children, and adolescents from the United States Food and Drug Administration. Daily doses of 50 mg/m 2 result in pharmacokinetic parameters that are similar to those observed in...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2012-01-01
|
| Series: | Clinical Medicine Insights: Pediatrics |
| Online Access: | https://doi.org/10.4137/CMPed.S8016 |